Skip to main content
  • Saved

made a Post

An in silico-in vitro Pipeline Identifying an HLA-A*02:01  KRAS G12V  Spliced Epitope Candidate for a Broad Tumor-Immune Response in Cancer Patients

An in silico-in vitro Pipeline Identifying an HLA-A*02:01 KRAS G12V Spliced Epitope Candidate for a Broad Tumor-Immune Response in Cancer Patients

Source : https://doi.org/10.3389/fimmu.2019.02572

Targeting CD8 T cells to recurrent tumor-specific mutations can profoundly contribute to cancer treatment. Some of these mutations are potential tumor antigens although they can be displayed by non-spliced epitopes only in a few patients, because of the low affinity of the mutated non-spliced peptides for the predominant HLA class I alleles.

Sign In or Register Today to Access This Content